These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2514360)

  • 21. Serotonin1B receptor activation mimics behavioral effects of presynaptic serotonin release.
    Rempel NL; Callaway CW; Geyer MA
    Neuropsychopharmacology; 1993 May; 8(3):201-11. PubMed ID: 8099482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role for the mesocortical dopamine system in the motivating effects of cocaine.
    Koob GF; Caine B; Markou A; Pulvirenti L; Weiss F
    NIDA Res Monogr; 1994; 145():1-18. PubMed ID: 8742805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain mechanisms of drug reward and euphoria.
    Wise RA; Bozarth MA
    Psychiatr Med; 1985; 3(4):445-60. PubMed ID: 2893431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "Designer" amphetamines: effects on behavior and monoamines with or without reserpine and/or alpha-methyl-para-tyrosine pretreatment.
    Martin-Iverson MT; Yamada N; By AW; Lodge BA
    J Psychiatry Neurosci; 1991 Dec; 16(5):253-61. PubMed ID: 1686728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functionally selective neurochemical afferents and efferents of the mesocorticolimbic and nigrostriatal dopamine system.
    Amalric M; Koob GF
    Prog Brain Res; 1993; 99():209-26. PubMed ID: 8108549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of CART in the reward/reinforcing properties of psychostimulants.
    Jaworski JN; Jones DC
    Peptides; 2006 Aug; 27(8):1993-2004. PubMed ID: 16766084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neural mechanisms of the reinforcing action of cocaine.
    Wise RA
    NIDA Res Monogr; 1984; 50():15-33. PubMed ID: 6440023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brain dopamine and reward.
    Wise RA; Rompre PP
    Annu Rev Psychol; 1989; 40():191-225. PubMed ID: 2648975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenylalkylamine stimulants, hallucinogens, and designer drugs.
    Glennon RA
    NIDA Res Monogr; 1990; 105():154-60. PubMed ID: 1678860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens.
    Bardo MT
    Crit Rev Neurobiol; 1998; 12(1-2):37-67. PubMed ID: 9444481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of reward pathways in the development of drug dependence.
    Wise RA
    Pharmacol Ther; 1987; 35(1-2):227-63. PubMed ID: 3321101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neural basis of psychomotor stimulant and opiate reward: evidence suggesting the involvement of a common dopaminergic system.
    Bozarth MA
    Behav Brain Res; 1986 Nov; 22(2):107-16. PubMed ID: 2878670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Designer psychostimulants: pharmacology and differences.
    Iversen L; White M; Treble R
    Neuropharmacology; 2014 Dec; 87():59-65. PubMed ID: 24456744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The neural substrates for the motor-activating properties of psychostimulants: a review of recent findings.
    Swerdlow NR; Vaccarino FJ; Amalric M; Koob GF
    Pharmacol Biochem Behav; 1986 Jul; 25(1):233-48. PubMed ID: 2875470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine.
    Hegadoren KM; Martin-Iverson MT; Baker GB
    Psychopharmacology (Berl); 1995 Apr; 118(3):295-304. PubMed ID: 7617822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Behavioral and neurochemical effects of amphetamine analogs that release monoamines in the squirrel monkey.
    Kimmel HL; Manvich DF; Blough BE; Negus SS; Howell LL
    Pharmacol Biochem Behav; 2009 Dec; 94(2):278-84. PubMed ID: 19766133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High versus low reactivity to a novel environment: behavioural, pharmacological and neurochemical assessments.
    Thiel CM; Müller CP; Huston JP; Schwarting RK
    Neuroscience; 1999; 93(1):243-51. PubMed ID: 10430488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function.
    Grace AA
    Drug Alcohol Depend; 1995 Feb; 37(2):111-29. PubMed ID: 7758401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacology and toxicology of amphetamine and related designer drugs.
    NIDA Res Monogr; 1989; 94():1-357. PubMed ID: 2514359
    [No Abstract]   [Full Text] [Related]  

  • 40. Localization of drug reward mechanisms by intracranial injections.
    Wise RA; Hoffman DC
    Synapse; 1992 Mar; 10(3):247-63. PubMed ID: 1557697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.